Stephane Bancel - Moderna CEO Director

M1RN34 Stock  BRL 13.07  0.41  3.04%   

Insider

Stephane Bancel is CEO Director of Moderna
Age 50
Phone617 714 6500
Webhttps://www.modernatx.com

Moderna Management Efficiency

The company has return on total asset (ROA) of 0.3526 % which means that it generated a profit of $0.3526 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.8369 %, meaning that it generated $0.8369 on every $100 dollars invested by stockholders. Moderna's management efficiency ratios could be used to measure how well Moderna manages its routine affairs as well as how well it operates its assets and liabilities.
Moderna has accumulated 599 M in total debt with debt to equity ratio (D/E) of 0.09, which may suggest the company is not taking enough advantage from borrowing. Moderna has a current ratio of 1.22, suggesting that it may not be capable to disburse its financial obligations in time and when they become due. Debt can assist Moderna until it has trouble settling it off, either with new capital or with free cash flow. So, Moderna's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Moderna sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Moderna to invest in growth at high rates of return. When we think about Moderna's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Qiang WuNew Oriental Education
50
Hideaki TakaseMitsubishi UFJ Financial
55
Jun OhtaSumitomo Mitsui Financial
65
TungJung HsiehNew Oriental Education
59
Katsunori TanizakiSumitomo Mitsui Financial
66
Sisi ZhaoNew Oriental Education
N/A
Taka SakaMitsubishi UFJ Financial
N/A
Yoshitaka ShibaMitsubishi UFJ Financial
62
Takeshi MikamiSumitomo Mitsui Financial
57
Atsushi MiyataMitsubishi UFJ Financial
59
Naomi HayashiMitsubishi UFJ Financial
58
Toru NakashimaSumitomo Mitsui Financial
60
Yoshihiro HyakutomeSumitomo Mitsui Financial
58
Zheng ZhaoNew Oriental Education
N/A
Zhihui YangNew Oriental Education
49
Randall ChafetzMitsubishi UFJ Financial
N/A
Toshiki OchiMitsubishi UFJ Financial
55
Hironori KamezawaMitsubishi UFJ Financial
62
Tetsuya YonehanaMitsubishi UFJ Financial
59
Jun OkahashiSumitomo Mitsui Financial
N/A
Toshikazu YakuSumitomo Mitsui Financial
61
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. MODERNA INC operates under Biotechnology classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 1800 people. Moderna (M1RN34) is traded on Sao Paulo Exchange in Brazil and employs 3,700 people.

Management Performance

Moderna Leadership Team

Elected by the shareholders, the Moderna's board of directors comprises two types of representatives: Moderna inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Moderna. The board's role is to monitor Moderna's management team and ensure that shareholders' interests are well served. Moderna's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Moderna's outside directors are responsible for providing unbiased perspectives on the board's policies.
Shannon Klinger, Chief Sec
James Mock, Chief Officer
Stephane Bancel, CEO Director
John Reynders, Chief Officer
Jerh Collins, Chief Officer
Lavina CFA, VP Relations
Juan Andres, Pres Expansion
Melissa Moore, Chief Board
Noubar Afeyan, Independent CoFounder
Stephen MD, President

Moderna Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Moderna a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Moderna Stock

When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.